Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6HX9B)

• Drug Name: Nevirapine Drug Info
• Synonyms: NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1]

• Therapeutic Class: Anti-HIV Agents
• Cross-matching ID:
  PubChem CID: 4463
  ChEBI ID: CHEBI:63613
  CAS Number: CAS 129618-40-2
  TTD Drug ID: DM6HX9B
  VARIDT Drug ID: DR00447
  INTEDE Drug ID: DR1142
  ACDINA Drug ID: D00464

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[15]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[16]
Tenofovir	DM1IS6U	Chronic hepatitis B virus infection		Approved	[15]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[17]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[18]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[17]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[17]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[19]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[20]
MK-1439	DM215WE	Human immunodeficiency virus infection	1C62	Approved	[21]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[3]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[22]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[24]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[23]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[23]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[25]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[23]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[26]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[27]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[29]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[33]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[34]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[35]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[29]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[6]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[78]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[79]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[80]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[81]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[82]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[82]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[83]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[84]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[85]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[86]

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[36]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[39]
Metronidazole	DMTIVEN	Abscess		Approved	[40]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[41]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[37]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[43]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[44]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[45]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[46]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[47]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[48]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[49]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[50]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[51]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[52]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[54]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[55]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[56]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[57]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[58]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[59]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[54]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[60]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[54]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[54]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[54]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[37]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[61]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[54]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[54]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[54]
Metronidazole	DMTIVEN	Abscess		Approved	[40]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[62]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[63]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[37]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[65]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[37]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[66]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[67]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[69]

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[70]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[37]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[72]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[73]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[74]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[75]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[76]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[77]

Drug(s) Affected By Sterol carrier protein 2 (SCP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[87]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[88]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[89]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[90]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[91]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[92]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[93]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[94]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[95]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[96]

Drug(s) Affected By MHC class II transactivator (CIITA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[97]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[98]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[99]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[101]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[98]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[102]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[103]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[104]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[94]

Drug(s) Affected By Protein NLRC5 (NLRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[105]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[106]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[106]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[87]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[93]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[107]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[108]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[94]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[109]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[96]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[110]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[13]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[112]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[115]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[13]

Drug(s) Affected By Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[116]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[117]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[118]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[119]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[120]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[121]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[125]

Drug(s) Affected By Pro-epidermal growth factor (EGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[126]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[127]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[129]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[130]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[131]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[106]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[87]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[88]

Drug(s) Affected By Thyroglobulin (TG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[133]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[134]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[106]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[106]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[135]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[136]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[137]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[107]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[108]

Drug(s) Affected By Interferon gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[138]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[139]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[140]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[141]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[142]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[143]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[144]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[145]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[146]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[147]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[148]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[149]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[150]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[151]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[152]
Selenium	DM25CGV	N. A.	N. A.	Approved	[153]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[154]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[155]

Drug(s) Affected By Apolipoprotein A-I (APOA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[156]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[157]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[158]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[159]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[160]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[161]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[87]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[162]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[163]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[164]

Drug(s) Affected By Albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[109]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[165]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[166]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[167]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[168]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[169]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[170]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[171]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[172]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[173]

Drug(s) Affected By Phosphatidylcholine-sterol acyltransferase (LCAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[158]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[175]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[176]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[93]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[177]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[177]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[109]

Drug(s) Affected By Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[178]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[179]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[180]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[181]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[182]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[149]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[183]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[152]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[184]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[178]

Drug(s) Affected By Keratin, type I cytoskeletal 18 (KRT18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[185]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[186]
Selenium	DM25CGV	N. A.	N. A.	Approved	[187]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[188]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[189]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[190]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[191]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[130]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[192]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[193]

Drug(s) Affected By Lipoprotein lipase (LPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[165]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[194]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[183]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[195]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[196]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[197]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[198]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[199]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[9]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[200]

Drug(s) Affected By Thyroid peroxidase (TPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[186]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[201]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[202]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[203]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[134]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[203]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[204]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[136]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]

Drug(s) Affected By Prostate-specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[194]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[205]
Selenium	DM25CGV	N. A.	N. A.	Approved	[206]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[207]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[208]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[209]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[210]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[211]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[106]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[212]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[213]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[214]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[13]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[13]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[178]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[215]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[178]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[216]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[217]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[218]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[181]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[219]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[149]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[151]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[220]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]

Drug(s) Affected By Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[221]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[221]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[221]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[222]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[223]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[224]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[225]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[226]
Selenium	DM25CGV	N. A.	N. A.	Approved	[206]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[227]

Drug(s) Affected By Cholesteryl ester transfer protein (CETP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[228]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[229]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[230]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[229]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[231]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[229]
Bezafibrate	DMZDCS0	Hypercholesterolaemia	5C80.0	Approved	[232]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[233]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[234]

Drug(s) Affected By Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[235]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[236]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[237]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[237]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[238]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[239]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[240]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[241]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[9]

Drug(s) Affected By Thyrotropin receptor (TSHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[134]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[202]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[136]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[242]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[202]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[243]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[244]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[245]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[233]

Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[246]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[13]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[13]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[13]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[247]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[248]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[249]

Drug(s) Affected By Sterol regulatory element-binding protein 1 (SREBF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[114]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[165]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[185]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[250]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[251]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[252]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[158]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[191]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[253]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma (PPARG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[254]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[255]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[256]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[257]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[196]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[258]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[259]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[260]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[261]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[262]

Drug(s) Affected By Leptin (LEP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[183]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[263]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[264]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[265]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[182]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[182]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[266]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[267]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[9]

Drug(s) Affected By CCAAT/enhancer-binding protein alpha (CEBPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[268]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[269]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[270]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[271]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[272]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[87]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[9]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[162]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[273]

Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[274]
Selenium	DM25CGV	N. A.	N. A.	Approved	[153]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[133]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[198]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[13]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[13]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[234]

Drug(s) Affected By Interleukin-24 (IL24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[180]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[13]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[149]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[13]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[275]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[276]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[13]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[276]

Drug(s) Affected By Adiponectin (ADIPOQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[182]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[182]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[277]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[278]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[182]
Cilazapril	DM4V6JA	Congestive heart failure	BD10	Approved	[279]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[280]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[182]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[281]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[282]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[13]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[13]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[13]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[13]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[13]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[87]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[13]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[283]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[284]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[13]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[13]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[178]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[285]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[286]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]

Drug(s) Affected By Glutathione S-transferase A1 (GSTA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[287]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[288]
Thiotepa	DMIZKOP	Breast cancer	2C60-2C65	Approved	[289]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[290]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[291]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[292]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[293]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[294]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[105]

Drug(s) Affected By Glutathione S-transferase A3 (GSTA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[295]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[295]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[93]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[296]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[111]
Atazanavir	DMSYRBX	Human immunodeficiency virus infection	1C62	Approved	[295]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[297]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[288]

Drug(s) Affected By Glutathione S-transferase P (GSTP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[298]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[107]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[299]
Chlorambucil	DMRKE63	Chronic lymphocytic leukaemia	2A82.0	Approved	[299]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[300]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[283]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Selenium	DM25CGV	N. A.	N. A.	Approved	[187]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[301]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[302]

Drug(s) Affected By Glutathione S-transferase Mu 1 (GSTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[298]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[303]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[304]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[305]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[276]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[276]
Methyldopa	DM5I621	Hypertension	BA00-BA04	Approved	[306]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[99]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[106]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[106]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Modulator	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[4]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[5]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[6]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[7]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[9]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[10]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Gene/Protein Processing	[11]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Gene/Protein Processing	[12]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[13]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Gene/Protein Processing	[9]
Cholesteryl ester transfer protein (CETP)	OTAGPPOE	CETP_HUMAN	Gene/Protein Processing	[12]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Protein Interaction/Cellular Processes	[14]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Gene/Protein Processing	[11]

References

• [1] Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
• [2] HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
• [3] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [4] Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
• [5] Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
• [6] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [7] RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
• [8] Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
• [9] Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
• [10] Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
• [11] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [12] Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. doi: 10.1161/ATVBAHA.109.192088. Epub 2009 Aug 10.
• [13] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [14] Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Chem Res Toxicol. 2012 Aug 20;25(8):1708-19. doi: 10.1021/tx300172s. Epub 2012 Jul 26.
• [15] Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
• [16] A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [18] Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
• [19] Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
• [20] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [21] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [22] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [23] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [24] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [25] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [26] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [27] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [28] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [29] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [30] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [31] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [32] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [33] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [34] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [35] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [36] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [37] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [38] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [39] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [40] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [41] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [42] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [43] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [44] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [45] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [46] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [47] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [48] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [49] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [50] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [51] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [52] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [53] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [54] Drug Interactions Flockhart Table
• [55] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [56] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [57] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [58] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [59] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [60] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [61] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [62] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [63] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [64] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [65] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [66] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [67] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [68] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [69] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [70] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [71] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [72] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [73] Drugs that may have potential CYP2B6 interactions.
• [74] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [75] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [76] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [77] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [78] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [79] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [80] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [81] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [82] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [83] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [84] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [85] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [86] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [87] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [88] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [89] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [90] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [91] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [92] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [93] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [94] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [95] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [96] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [97] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [98] Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid. Haematologica. 2007 Jan;92(1):115-20.
• [99] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [100] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [101] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [102] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [103] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [104] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [105] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [106] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [107] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [108] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [109] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [110] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [111] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [112] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [113] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [114] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [115] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [116] Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
• [117] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [118] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [119] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [120] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [121] Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
• [122] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [123] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [124] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [125] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [126] Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Int J Gynecol Cancer. 2009 Feb;19(2):214-22. doi: 10.1111/IGC.0b013e31819bcb75.
• [127] N-O Reduction and ROS-Mediated AKT/FOXO1 and AKT/P53 Pathways Are Involved in Growth Promotion and Cytotoxicity of Cyadox. Chem Res Toxicol. 2018 Nov 19;31(11):1219-1229. doi: 10.1021/acs.chemrestox.8b00194. Epub 2018 Oct 11.
• [128] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [129] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [130] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [131] Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
• [132] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [133] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [134] Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
• [135] Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6. doi: 10.1210/jc.2002-021834.
• [136] Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab. 2005 Oct;90(10):5663-71. doi: 10.1210/jc.2005-0367. Epub 2005 Jul 19.
• [137] Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007 Dec;17(12):1189-200. doi: 10.1089/thy.2007.0215.
• [138] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [139] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [140] Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res. 2007 Jul;75(1):36-42. doi: 10.1016/j.antiviral.2006.11.008. Epub 2006 Dec 13.
• [141] Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother. 2005 Sep;56(3):502-6. doi: 10.1093/jac/dki251. Epub 2005 Jul 8.
• [142] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [143] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [144] The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim Biophys Acta. 2002 Dec 16;1593(1):29-36. doi: 10.1016/s0167-4889(02)00328-2.
• [145] [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
• [146] Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. Chemotherapy. 1998 May-Jun;44(3):174-80. doi: 10.1159/000007112.
• [147] Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. Chem Res Toxicol. 2016 Nov 21;29(11):1793-1795. doi: 10.1021/acs.chemrestox.6b00393. Epub 2016 Nov 9.
• [148] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [149] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [150] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [151] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [152] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [153] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [154] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [155] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [156] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [157] Quercetin represses apolipoprotein B expression by inhibiting the transcriptional activity of C/EBP. PLoS One. 2015 Apr 15;10(4):e0121784. doi: 10.1371/journal.pone.0121784. eCollection 2015.
• [158] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [159] Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism. 2004 Jun;53(6):766-71. doi: 10.1016/j.metabol.2003.11.027.
• [160] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [161] The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
• [162] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [163] Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol. 2002 Apr-Jun;1(2):85-9.
• [164] Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1783-9. doi: 10.1161/hq1001.096624.
• [165] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [166] A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
• [167] The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
• [168] Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
• [169] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [170] Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
• [171] [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
• [172] Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
• [173] Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
• [174] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [175] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [176] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [177] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [178] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [179] Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010 Jul;46(10):1848-55. doi: 10.1016/j.ejca.2010.03.026. Epub 2010 Apr 17.
• [180] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [181] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [182] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [183] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [184] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [185] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [186] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [187] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [188] The stability of cytokeratin 18 in human liver cells during colchicine-induced microtubule disruption. Food Chem Toxicol. 2001 Jan;39(1):85-9. doi: 10.1016/s0278-6915(00)00113-7.
• [189] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [190] Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
• [191] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [192] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [193] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [194] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [195] Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol. 1999 Apr;47(4):433-9. doi: 10.1046/j.1365-2125.1999.00920.x.
• [196] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [197] Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine. Environ Mol Mutagen. 2007 Apr-May;48(3-4):179-89. doi: 10.1002/em.20245.
• [198] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [199] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [200] Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR Res. 2007;2007:36092. doi: 10.1155/2007/36092.
• [201] Identification of classifiers for increase or decrease of thyroid peroxidase activity in the FTC-238/hTPO recombinant cell line. Environ Sci Technol. 2011 Sep 15;45(18):7906-14. doi: 10.1021/es200475k. Epub 2011 Aug 24.
• [202] The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm. 2007 Jun;22(3):443-9. doi: 10.1089/cbr.2006.319.A.
• [203] Arsenic trioxide and reduced glutathione act synergistically to augment inhibition of thyroid peroxidase activity in vitro. Biol Trace Elem Res. 2015 May;165(1):110-7. doi: 10.1007/s12011-015-0230-x. Epub 2015 Jan 17.
• [204] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [205] Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
• [206] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [207] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [208] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [209] Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
• [210] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
• [211] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [212] Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. J Urol. 2006 Jul;176(1):354-60. doi: 10.1016/S0022-5347(06)00516-7.
• [213] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [214] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [215] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [216] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [217] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [218] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [219] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [220] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [221] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [222] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [223] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [224] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [225] Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
• [226] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [227] Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
• [228] Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol. 1999 Summer;6(2):85-90.
• [229] Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
• [230] Arsenic trioxide suppresses liver X receptor and enhances cholesteryl ester transfer protein expression without affecting the liver X receptor in HepG2 cells. Chem Biol Interact. 2016 Oct 25;258:288-96. doi: 10.1016/j.cbi.2016.09.009. Epub 2016 Sep 10.
• [231] Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells. Int J Mol Med. 2005 Oct;16(4):717-22.
• [232] Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res. 2003 Aug;44(8):1462-9. doi: 10.1194/jlr.M300008-JLR200. Epub 2003 May 16.
• [233] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [234] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [235] Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer. 2015 May 14;14:103. doi: 10.1186/s12943-015-0367-4.
• [236] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [237] Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. Brain Res Mol Brain Res. 2001 Feb 19;87(1):100-8. doi: 10.1016/s0165-3806(00)00154-1.
• [238] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [239] The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:44-9. doi: 10.1046/j.1365-2036.2000.014s1044.x.
• [240] Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer. 2007 Oct 15;121(8):1697-704. doi: 10.1002/ijc.22867.
• [241] Regulation of keratinocyte growth factor and scatter factor in cyclosporin-induced gingival overgrowth. J Oral Pathol Med. 2004 Aug;33(7):391-7. doi: 10.1111/j.1600-0714.2004.00223.x.
• [242] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [243] Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line. Int J Endocrinol. 2015;2015:978371. doi: 10.1155/2015/978371. Epub 2015 Jan 29.
• [244] Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
• [245] BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.
• [246] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [247] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [248] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [249] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [250] Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. J Pharmacol Exp Ther. 2018 Mar;364(3):452-461. doi: 10.1124/jpet.117.243105. Epub 2018 Jan 9.
• [251] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [252] Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
• [253] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [254] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [255] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [256] The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
• [257] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
• [258] Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
• [259] Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
• [260] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [261] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [262] Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
• [263] Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010 Apr 1;140(1):73-81. doi: 10.1016/j.ijcard.2008.11.017. Epub 2008 Dec 6.
• [264] [Quercetin affects leptin and its receptor in human gastric cancer MGC-803 cells and JAK-STAT pathway]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jan;28(1):12-6.
• [265] Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab. 2000 Aug;85(8):2678-84. doi: 10.1210/jcem.85.8.6733.
• [266] The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
• [267] Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol. 2009 Mar 20;133(1):23-31. doi: 10.1016/j.ijcard.2007.11.058. Epub 2008 Jan 15.
• [268] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [269] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [270] C/EBPalpha inactivation in FAK-overexpressed HL-60 cells impairs cell differentiation. Cell Signal. 2006 Jul;18(7):955-63. doi: 10.1016/j.cellsig.2005.08.014. Epub 2005 Oct 14.
• [271] Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):204-9. doi: 10.1093/abbs/gmq130. Epub 2011 Jan 21.
• [272] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [273] The potential effects of HECTD4 variants on fasting glucose and triglyceride levels in relation to prevalence of type 2 diabetes based on alcohol intake. Arch Toxicol. 2022 Sep;96(9):2487-2499. doi: 10.1007/s00204-022-03325-y. Epub 2022 Jun 17.
• [274] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [275] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [276] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [277] Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007 Jun;28(12):1440-7. doi: 10.1093/eurheartj/ehm101. Epub 2007 May 5.
• [278] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [279] Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J. 2009 Dec;73(12):2282-7. doi: 10.1253/circj.cj-09-0387. Epub 2009 Sep 29.
• [280] Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs. Life Sci. 2020 Jun 15;251:117607. doi: 10.1016/j.lfs.2020.117607. Epub 2020 Mar 30.
• [281] (9)-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPAR induction: A possible evidence for the cancellation of PPAR/-mediated inhibition of PPAR in MDA-MB-231?cells. Arch Biochem Biophys. 2019 Feb 15;662:219-225. doi: 10.1016/j.abb.2018.12.011. Epub 2018 Dec 13.
• [282] Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol. 2006 Jul;155(1):167-76. doi: 10.1530/eje.1.02175.
• [283] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [284] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [285] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [286] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [287] Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
• [288] Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis. FASEB J. 2013 Aug;27(8):3198-208. doi: 10.1096/fj.12-222745. Epub 2013 May 6.
• [289] Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
• [290] Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci. 2001 Jan;59(1):118-26.
• [291] Acetaminophen-induced hepatocyte injury: C2-ceramide and oltipraz intervention, hepatocyte nuclear factor 1 and glutathione S-transferase A1 changes. J Appl Toxicol. 2019 Dec;39(12):1640-1650. doi: 10.1002/jat.3881. Epub 2019 Aug 6.
• [292] Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res. 1991 Jan 15;51(2):587-94.
• [293] Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. Gynecol Obstet Invest. 2011;71(2):104-11. doi: 10.1159/000320744. Epub 2010 Dec 9.
• [294] Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol. 2002 Dec;137(7):1100-6. doi: 10.1038/sj.bjp.0704972.
• [295] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [296] Simulation of interindividual differences in inactivation of reactive para-benzoquinone imine metabolites of diclofenac by glutathione S-transferases in human liver cytosol. Toxicol Lett. 2016 Jul 25;255:52-62.
• [297] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [298] Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.
• [299] The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug;294(2):480-7.
• [300] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [301] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [302] Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol. 2004;51(1):207-12.
• [303] Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Jan;13(1):57-64. doi: 10.1002/ibd.20004.
• [304] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [305] Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. Drug Alcohol Depend. 2010 Jun 1;109(1-3):190-7. doi: 10.1016/j.drugalcdep.2010.01.010. Epub 2010 Feb 18.
• [306] Inhibition of human glutathione S-transferases by dopamine, alpha-methyldopa and their 5-S-glutathionyl conjugates. Chem Biol Interact. 1994 Jan;90(1):87-99.